<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027165</url>
  </required_header>
  <id_info>
    <org_study_id>20-502</org_study_id>
    <nct_id>NCT05027165</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab</brief_title>
  <acronym>PRECISION</acronym>
  <official_title>Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab (PRECISION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LMU Klinikum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, Munich, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asklepios Lung Clinic, Munich-Gauting, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Radiology, University Hospital, LMU Munich, Munich, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute for Medical Information Processing, Biometry and Epidemiology, LMU MÃ¼nchen, Munich, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Medicine II, University Hospital, LMU Munich, Munich, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Immunoanalytics Research Group Tissue Control of Immunocytes, Helmholtz Center Munich, Munich, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>LMU Klinikum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional single-center explorative biomarker study aims at longitudinal&#xD;
      comprehensive characterization (molecular genetics, immunological, morphological, image-based&#xD;
      and microbial features) of the patient (host) and tumor as well as changes during standard&#xD;
      treatment and in case of recurrent disease in inoperable stage III non-small cell lung cancer&#xD;
      (NSCLC). Comprehensive analysis will include peripheral blood cellular and humoral&#xD;
      immunophenotyping, circulating tumor DNA and gut/saliva microbiota analyses. 18F-FDG-PET/CT&#xD;
      before, 6 weeks, 6- and 12-months after chemoradiotherapy as well as daily in course of&#xD;
      radiation treatment cone-beam-CT and/or MRI imaging are included for morphological analysis.&#xD;
      This study will provide valuable information of predictive biomarkers in patients with stage&#xD;
      III NSCLC treated with durvalumab maintenance treatment after concurrent chemoradiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enrol 40 patients with stage III inoperable non-small cell lung cancer (NSCLC)&#xD;
      who received standard chemoradiotherapy followed by maintenance therapy with PD-L1 inhibition&#xD;
      (durvalumab) according to the current European Medicines Agency (EMA) approval.&#xD;
&#xD;
      The oncological treatment is carried out according to the international standards of&#xD;
      radiation oncology/medical oncology. These are implemented by the department of radiation&#xD;
      oncology at the University Hospital Munich (LMU) in their SOPs. Therefore, all patients will&#xD;
      be treated with concurrent platinum-based chemoradiotherapy followed by durvalumab&#xD;
      maintenance treatment 12 months after the end of chemoradiotherapy at the department of&#xD;
      radiation oncology (University Hospital Munich (LMU)). Comprehensive characterization of all&#xD;
      patients includes immunophenotyping of peripheral blood mono-nuclear cells, ctDNA as well as&#xD;
      gut/saliva microbiome analyses and will be performed before, after 15 fractions of&#xD;
      radiotherapy, at the end of concurrent chemoradiotherapy as well as 3-, 6- and 12 months&#xD;
      after start of durvalumab.&#xD;
&#xD;
      18F-FDG-PET/CT will be performed 5-10 d before start of radiotherapy, 6 weeks, 6 months,12&#xD;
      and 24 months after the end of chemoradiotherapy. Lung function will be assessed before start&#xD;
      of radiotherapy, at the end and 6 weeks after chemoradiotherapy as well as 3-, 6- and 12, 18,&#xD;
      24 months after start of durvalumab.&#xD;
&#xD;
      Follow-up will be performed by the department of radiation oncology at the University&#xD;
      Hospital Munich (LMU) according to the clinical SOPs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive biomarker for progression-free survival at 12 and 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>To identify early immunological and morphological biomarkers and their dynamic changes to predict progression-free survival at 12 and 24 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive biomarkers for progression-free survival, overall survival, response rate, local and distant tumor control</measure>
    <time_frame>24 months</time_frame>
    <description>To identify predictive biomarkers for progression-free survival at 6 and 18 months after chemoradiotherapy and overall survival and response rate, local and distant tumor control at 6 weeks, 6-, 12-, 18 and 24 months from the end of chemoradiotherapy.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Oncology</condition>
  <condition>Biomarker</condition>
  <condition>NSCLC, Stage III</condition>
  <condition>Durvalumab</condition>
  <condition>Chemoradiotherapy</condition>
  <arm_group>
    <arm_group_label>Observational group</arm_group_label>
    <description>In this cohort, 40 NSCLC patients with indication for chemoradiotherapy followed by durvalumab maintenance treatment (&quot;standard of care&quot;) will be consecutively recruited.&#xD;
Comprehensive characterization of all patients includes immunophenotyping of peripheral blood mono-nuclear cells, ctDNA as well as gut/saliva microbiome analyses and will be performed before, after 15 fractions of radiotherapy, at the end of concurrent chemoradiotherapy as well as 3-, 6- and 12 months after start of durvalumab.&#xD;
18F-FDG-PET/CT will be performed 5-10 d before start of radiotherapy, 6 weeks, 6 months,12 and 24 months after the end of radiochemotherapy. Lung function will be asssed before start of radiotherapy, at the end and 6 weeks after chemoradiotherapy as well as 3-, 6- and 12, 18, 24months after start of durvalumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Observational group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Short circulating tumor total nucleic acid (ctTNA: ctDNA and ctRNA) within blood sample and&#xD;
      possible mutations will be analysed at six different time points (blood sample will be&#xD;
      collected 5-10 d before, after 15 fractions, at the end of concurrent chemoradiotherapy as&#xD;
      well as 3-, 6- and 12 months after start of durvalumab).&#xD;
&#xD;
      Blood samples will be evaluated using the Oncomine Pan-Cancer Cell free Assay (Life&#xD;
      Technololgies) NGS (next generation sequencing).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will enrol 40 patients with stage III inoperable non-small cell lung cancer&#xD;
        (NSCLC) who received standard chemoradiotherapy followed by maintenance therapy with PD-L1&#xD;
        inhibition (durvalumab) at the department of radiation oncology, University Hospital Munich&#xD;
        (LMU).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient age â¥ 18 years&#xD;
&#xD;
          -  Histologically/cytologically confirmed diagnosis of non-small-cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Patients with non-operable NSCLC in tumor stage III A/B/C after UICC 8&#xD;
&#xD;
          -  Eligible for platinum-based concurrent chemoradiotherapy followed by durvalumab&#xD;
             maintenance treatment&#xD;
&#xD;
          -  No invasive carcinoma in the last five years.&#xD;
&#xD;
          -  ECOG Performance Status 0-2&#xD;
&#xD;
          -  Lung function parameters (before or after bronchodilation): FEV1 â¥ 1.0 L and/or&#xD;
             DLCO-SB â¥ 40%&#xD;
&#xD;
          -  A maximum of two cycles of induction chemotherapy are permissible before start of&#xD;
             chemoradiotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Simultaneous participation in another clinical trial&#xD;
&#xD;
          -  Mixed histology of small-cell and non-small-cell lung cancer&#xD;
&#xD;
          -  Brain metastases confirmed by a contrast enhanced cMRI&#xD;
&#xD;
          -  Prior receipt of an immunotherapy or investigational medicinal product&#xD;
&#xD;
          -  Previous exposure to an anti-PD-1 or anti-PD-L1 antibody&#xD;
&#xD;
          -  Pneumonitis â¥ Grade 2 as a result of prior radio-/chemoradiotherapy&#xD;
&#xD;
          -  Patients with a non-active disease in the last 5 years can be included, but only after&#xD;
             consultation with the responsible investigator of the study or his representative&#xD;
&#xD;
          -  Primary immunodeficiencies in previous history&#xD;
&#xD;
          -  Prior Interstitial lung disease (ILD)&#xD;
&#xD;
          -  Prior autoimmune disease&#xD;
&#xD;
          -  Previous organ transplantation with subsequent therapeutic immunosuppression&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farkhad Manapov, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LMU University hospital, Munich, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Farkhad Manapov, PhD MD</last_name>
    <phone>004989440057561</phone>
    <email>Farkhad.Manapov@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lukas KÃ¤smann, MD</last_name>
    <phone>004989440057561</phone>
    <email>Lukas.Kaesmann@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LMU University Hospital</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farkhad Manapov, PhD MD</last_name>
      <phone>004989440057561</phone>
      <email>Farkhad.Manapov@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Lukas KÃ¤smann, MD</last_name>
      <phone>004989440057561</phone>
      <email>Lukas.Kaesmann@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Farkhad Manapov, PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukas KÃ¤smann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julian Taugner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chukwuka Eze, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LMU Klinikum</investigator_affiliation>
    <investigator_full_name>Farkhad Manapov</investigator_full_name>
    <investigator_title>PD Dr. med Farkhad Manapov</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Stage III</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data is available on request due to privacy/ethical restrictions.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

